Success Metrics

Clinical Success Rate
20.0%

Based on 1 completed trials

Completion Rate
20%(1/5)
Active Trials
1(17%)
Results Posted
300%(3 trials)
Terminated
4(67%)

Phase Distribution

Ph phase_2
2
33%
Ph phase_3
1
17%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(1)
Terminated(4)

Detailed Status

Terminated4
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
20.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

recruiting117%
terminated467%
completed117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
terminatedphase_2

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

NCT04059484
terminatedphase_1

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

NCT03284957
completedphase_1

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

NCT04940026
terminatedphase_1

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

NCT05126329
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01042379Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting
NCT04059484Phase 2

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Terminated
NCT03284957Phase 1

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Terminated
NCT04940026Phase 1

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Completed
NCT05126329Phase 1

Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Terminated
NCT05128773Phase 3

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6